Drug Trial Radar · NCT05059951
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
Last checked: Nov 20, 2026Latest source record: Jun 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15,000
Planned (sponsor's estimate)
Start
Oct 3, 2021
Primary completion
Sep 15, 2026
Study completion Mar 1, 2028
Sponsor
- Lead sponsor
- Hunan Province Tumor HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 28, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
Although several clinical trials provide evidence for efficacy benefit for Checkpoint Inhibitors plus chemotherapy for lung cancer. However, there was rare evidence for clinical evidence in Hunan province.
Conditions
- Non Small Cell Lung Cancer
Interventions
Immune checkpoint inhibitorDrug
Chemotherapy follow the guild line.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: Time from first subject dose to study completion, or up to 36 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.